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Background: Low-dose aspirin can cause gastric and duodenal ulceration, hereafter called peptic ulcer disease
(PUD). Predisposition is thought to be related to clinical and genetic factors; our aim was to identify genetic
risk factors associated with aspirin-induced PUD.
Methods: Patients (n=1478) were recruited from 15 UK hospitals. Cases (n=505) were defined as patients with
endoscopically confirmed PUD within 2 weeks of using aspirin and non-aspirin Non-Steroidal Anti-Inflam-
matory Drugs (NSAIDs). They were compared to two control groups: patients with endoscopically confirmed
PUD without any history of NSAID use within 3 months of diagnosis (n=495), and patients with no PUD on
endoscopy (n=478). A genome-wide association study (GWAS) of aspirin-induced cases (n=247) was com-
pared to 476 controls. The results were validated by replication in another 84 cases and 162 controls.
Findings: The GWAS identified one variant, rs12678747 (p=1¢65£107) located in the last intron of EYA1 on
chromosome 8. The association was replicated in another sample of 84 PUD patients receiving aspirin
(p=0¢002). Meta-analysis of discovery and replication cohort data for rs12678747, yielded a genome-wide
significant association (p=3¢12£1011; OR=2¢03; 95% CI 1¢65-2¢50). Expression of EYA1 was lower at the gas-
tric ulcer edge when compared with the antrum.
Interpretation: Genetic variation in an intron of the EYA1 gene increases the risk of endoscopically confirmed
aspirin-induced PUD. Reduced EYA1 expression in the upper gastrointestinal epithelium may modulate risk,
but the functional basis of this association will need mechanistic evaluation.
Funding: Department of Health Chair in Pharmacogenetics, MRC Centre for Drug Safety Science and the Barts
Cardiovascular NIHR Biomedical Research Centre, British Heart Foundation (BHF)
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Low-dose aspirin (75-325mg/day) is taken by up to 30% of the
general population [1], its use rising with age. Approximately 30 mil-
lion people in the US take non-aspirin non-steroidal anti-inflammatory drug (NSAIDs) every day [2]. Up to 25% of all reported
adverse drug reactions (ADRs) can be attributed to NSAIDs [3]. Upper
gastrointestinal (GI) or peptic ulceration is one of the commonest
ADRs: a population-based UK cohort study showed an incidence of
NSAID-induced symptomatic, uncomplicated peptic ulcer disease of
1¢03 cases per 1000-person years, with a relative risk of 2¢9 (CI 2¢3-
3¢6) for aspirin and 4¢0 (CI 3¢2-5¢1) for non-aspirin NSAID users, com-
pared to non-users [4]. Low-dose aspirin also increases the risk of
major GI bleeding [5], especially in those over the age of 75 years [6].
Our epidemiological study of 18,820 patients showed that NSAIDs
(including aspirin) were the commonest cause of ADR-related hospi-
tal admission, often due to upper GI ulceration and its complications
[7]. It has been estimated that annually between 5000-16500 deaths
Research in context
Evidence before this study
Aspirin and non-aspirin NSAIDs are amongst the commonest
causes of peptic ulcer disease, affecting either the stomach and/
or duodenum
Inhibition of cyclo-oxygenase 1 by NSAIDs reducing mucosal
protection to gastric acid by prostaglandins is the most widely
accepted mechanism for the tissue injury
The mechanism of NSAID-induced peptic ulceration is com-
plex, and multiple interacting pathways in addition to mucosal
protection are involved.
Genetic predisposing factors have been postulated and have
focused on genes encoding cytochrome P450 and the cyclo-
oxygenase enzymes, with contradictory findings.
Added value of this study
We performed a genome-wide association study that identified
an intronic variant in the EYA1 gene associated with endoscopi-
cally confirmed aspirin-induced peptic ulceration
Replication was shown in another cohort with aspirin-
induced peptic ulceration, but the locus was not associated
with ulceration associated with non-aspirin NSAIDs.
RNA sequencing of gastric biopsy samples from patients
with bleeding peptic ulcers showed EYA1 expression at the
ulcer edge was lower than in the antrum.
Implications
We provide evidence that EYA1 is a novel locus that predisposes
to endoscopically confirmed aspirin-induced peptic ulceration.
This may provide a potential pharmacogenetic biomarker and
may serve as a target for future preventive anti-ulcer therapies.
2 S. Bourgeois et al. / EBioMedicine 74 (2021) 103728in the USA and between 400-1000 deaths in the UK are directly
attributable to NSAID-induced upper GI ulceration and GI hemor-
rhage [810].
Genetic factors may play a role in predisposing to NSAID-
induced peptic ulcer disease (PUD) [11]. Many NSAIDs are metab-
olised by cytochrome P450 2C9 (CYP2C9), but candidate-gene
studies of CYP2C9 polymorphisms have provided conflicting evi-
dence, with some reporting that low-activity CYP2C9 gene var-
iants predispose to NSAID GI complications [12,13], while others
found no association [14]. Indeed a meta-analysis suggested that
CYP2C9*3 but not *2 was a strong predictor of NSAID-induced
ulcer and bleeding risk [15]. We evaluated the whole CYP2C gene
cluster on chromosome 10 using the cohort reported herein, and
found an association with a CYP2C19*17 gain of function polymor-
phism [16]. This was postulated to affect the metabolism of
arachidonic acid, which is known to play a role in PUD.[17] Stud-
ies of pharmacodynamic genes such as cyclooxygenase 1 and 2
(COX-1 and COX-2), the pharmacological targets of most NSAIDs,
again have produced contradictory findings [1820].
Given that there are few consistent, reproducible data supporting
the role of pharmacokinetic or pharmacodynamic gene polymor-
phisms in the pathogenesis of NSAID-induced GI complications, we
have undertaken a genome wide association study (GWAS) to iden-
tify, using a “hypothesis-free” approach, common novel genetic loci
as risk factors for endoscopically confirmed aspirin-induced PUD. We
focused on aspirin because this was the most common NSAID associ-
ated with peptic ulceration in our cohort.2. Methods
2.1. Patients and outcomes
Our study was designed to identify and recruit patients with
NSAID-induced (including low-dose aspirin) PUD. Patient recruit-
ment for the study has been previously described [16]. Briefly,
patients who had undergone endoscopy for suspected PUD between
July 2005 and June 2011 were identified from endoscopy databases
at 15 hospitals in the United Kingdom and invited by telephone or e-
mail to take part in the study. Patients were also recruited prospec-
tively (from January 2008 onwards) as hospital inpatients or when
attending for endoscopy.
The final study cohort consisted of 1478 patients, who fell into
3 distinct phenotypes: cases were defined as patients with endo-
scopically confirmed PUD within 2 weeks of using NSAIDs
(n=505). PUD was defined either from the endoscopy reports as a
mucosal break 3mm in diameter, or from the description of the
endoscopist if size was not specified. These were compared to
two control groups:
 patients with endoscopically confirmed PUD who did not have
any history of NSAID use within 3 months of diagnosis (control
group A; n=495); and
 patients with no PUD on endoscopy, some of whom were taking
NSAID (control group B; n=478).
2.2. Ethics
Approval for the study, which conforms to the Declaration of Hel-
sinki, came from the Liverpool (Adults) Research Ethics Committee
(reference number 07/H1005/119) and informed consent was
obtained from all eligible patients.
2.3. Genotyping, data calling and QC
Of the 1478 patients recruited, DNA from 723 patients (PUD cases,
n=247 (all aspirin-induced); control group A, n=245; control group B,
n=231) were assayed on the Illumina Omni 2¢5 single nucleotide
polymorphism (SNP) array (Illumina, San Diego, CA, USA); bead chips
were scanned with an iScan. Intensity data, normalized according to
the standard Illumina algorithm, was extracted and genotypes called
using Illuminus [21]. Sample call rate was calculated and Illuminus
re-run was performed using only samples with a call rate of at least
90% to improve cluster definition.
Samples having a call rate of less than 95% or having autosomal het-
erozygosity values in the tail of the distributionwere excluded. Chromo-
some X heterozygosity was used to predict gender (samples with values
less than 4% are predicted as male, those with values over 15% are pre-
dicted as female); this was compared to the gender in the original docu-
mentation, and discrepancies resolved, or samples excluded. A pairwise
comparison was run for all samples using 400 independent common
SNPs to identify duplicate samples. Genotypes for each sample were
compared to the molecular fingerprint  a set of 26 markers typed
using the MassArray iPLEX platform (Agena Bioscience Inc., San Diego,
CA, USA)- to eliminate the possibility of arraying errors.
A principal component analysis (PCA) was performed together
with Hapmap 3 [22] samples in order to identify non-European
ancestry outliers. Identity by descent (IBD) was calculated for all pairs
of samples using PLINK 1¢9 [23,24], and one sample would be
excluded from each pair for which pi-hat was greater than or equal
to 0¢25 (second degree relatives). A flowchart of the whole sample
QC process is available in Supplementary Figure 1.
S. Bourgeois et al. / EBioMedicine 74 (2021) 103728 3All variants with a call rate below 98% were excluded, and those
with a minor allele frequency (MAF) below 3% were excluded if their
call rate was below 99%. Variants with an exact p -value for deviation
from Hardy-Weinberg equilibrium of below 104 were also excluded
(Supplementary Figure 2).
2.4. Imputation
Prior to phasing using SHAPEIT2 [25], variants whose MAF was
below 1% were excluded; the imputation was carried out with
IMPUTE2 [26], using the multi-ethnic 1000 Genomes Project Phase 3
[27] integrated variant set release in NCBI build 37 as the reference
panel. Post-imputation, variants with an info score below 0¢8 were
excluded, as well as variants with a non-unique genomic location.
2.5. Statistics
To maximise power for discovery of loci associated with NSAID-
induced PUD, we considered all controls, irrespective of NSAID use.
Consequently, by design, NSAID use was fully confounded with out-
come since all cases were NSAID users. Potential confounders (demo-
graphic and clinical) tested univariately for association with the
outcome were: age, gender, smoking status (three categories: non-
smoker, ex-smoker, current smoker), alcohol consumption (AUDIT
[28]), calcium supplements (binary), selective serotonin reuptake
inhibitor (SSRI) (binary), steroids (binary), anti-coagulants (binary),
anti-platelet agents (binary), anti-secretory drugs (binary), proton
pump inhibitors (ppi) (binary), Helicobacter pylori (H. pylori) status
(binary), history of H. pylori (binary), history of gastric disease
(binary), history of duodenal disease (binary), history of gastro-intes-
tinal disease (binary), history of cardiovascular disease (binary), his-
tory of respiratory disease (binary), history of renal disease (binary),
history of neurological disease (binary), history of diabetes mellitus
(binary), history of hepatic disease (binary), and history of muscular
problems (binary). History of cardiovascular disease, history of diabe-
tes mellitus, and history of respiratory disease were excluded
because of their likely confounding with NSAID use, and hence out-
come, by design.
To avoid collinearity, all potential confounders were checked for
pairwise correlation using Pearson’s correlation test in R. The afore-
mentioned confounders were included in a stepwise variable selec-
tion in R [29] to determine the variables to be used as covariates in
association analyses. Association testing of each SNP was undertaken
in a logistic regression framework, under an additive dosage model
in the minor allele, using SNPTEST [30], with a MAF cut-off of five
percent, and genomic control inflation was calculated. Our study
design allowed for the possibility that we would identify variants
associated with NSAID use in the general population, and so we also
tested for association of identified loci with NSAID use amongst con-
trols only and excluded from replication any that demonstrated nom-
inal significance (p<0¢05). The Manhattan plot was prepared using an
in-house Python script. Regional visualisations of the Manhattan plot
were produced using LocusZoom software [31].
2.6. Replication cohort
From the total number of patients recruited, 515 self-reported
white European patients with endoscopically confirmed PUD (206
cases) and 309 controls (124 control group A, 185 control group B)
were included in the replication cohort. Cases and controls included
in the replication cohort were recruited later than those included in
the discovery cohort. Lead variants with a p-value below 5*106 in a
clear delineated LD block in the association with aspirin-induced
PUD in the discovery cohort were subsequently typed in the replica-
tion cohort using the Agena MassArray iPLEX platform (Agena Biosci-
ence Inc, San Diego, CA, USA) according to the manufacturer’sprotocols and subsequently tested in using the same logistic regres-
sion model and methodology in SNPTEST as previously described.
SNPs were excluded when MAF<0¢01, call rate <95% and HWE
p>0¢0001 [exact test]. Samples were excluded if genotyping call rate
<90%. Meta-analysis combining the association summary data of
both cohorts was undertaken under an inverse-variance weighted
fixed-effects model using GWAMA [32].
2.7. RNA sequencing of gastric biopsies
A subset of 10 PUD patients (3 aspirin only, 4 aspirin plus other
NSAID, 3 non-aspirin NSAID) from the discovery cohort were
included in the biopsy cohort. Biopsies were taken from both antrum
and ulcer edge and were typically 2-3mm in size. Total RNA extrac-
tion, from a single biopsy sample was undertaken, using the
miRNeasy mini kit (QIAGEN Sciences, Germantown, MD, USA)
according to the manufacturers protocol. RNA integrity number (RIN)
was determined using the Agilent 2100 Bioanalyser with the RNA
Nano 6000 kit according to the manufacturers protocol (Agilent Tech-
nologies, Santa Clara, CA, USA). A RIN cut-off of 7 was applied to the
samples. RNA samples were poly-A selected using Invitrogen Dyna-
beads (Thermo Fisher Scientific, Waltham, MA, USA) and RNA-seq
libraries were prepared from 50ng poly-A RNA using the Epicentre
ScriptSeq v2 RNA-Seq library preparation kit according the manufac-
turers protocol (Illumina Inc., San Diego, CA, USA) Following 10 cycles
of amplification, libraries were purified using Ampure XP beads
(Beckman Coulter, Pasadena, CA, USA) and quantified using the
InvitrogenTM QubitTM fluorometer (Thermo Fisher Scientific, Wal-
tham, MA, USA) with size distribution assessed using the Agilent
2100 Bioanalyser. Amplified libraries were multiplexed as 5 individ-
ual pools, each with 6 libraries per pool. Sequencing of the pooled
libraries was undertaken using the HiSeq platform (Illumina Inc., San
Diego, CA, USA). Transcript sequences were mapped to human
genome 19 (hg19) reference sequence using TopHat 2¢0¢8 [33] and
bowtie 2¢1¢0 [34]. Paired end mapping was applied to trimmed data
and counts were reported at gene level.
2.8. Role of funders
Funders were not involved in the conception, undertaking, or
interpretation of the research findings.
3. Results
Of the 723 samples genotyped on the Illumina Omni 2¢5 SNP
array, eight samples were excluded from all further analysis follow-
ing a decision to withdraw from the study, one patient was found to
have previously undergone GI surgery, and one had previous NSAID
treatment, 26 samples did not cluster with the remainder of the
cohort in the PCA (non-European ancestry outliers), one had an
“other” self-declared ethnicity, and 10 samples had a missing pheno-
type, leaving 676 samples for analysis, 235 of which were cases
(Table 1). All cases were taking aspirin, with eight also concomitantly
taking another NSAID (Table 1).
A total of 1,524,956 variants were used for imputation, resulting
in a set of 82,310,144 variants post-imputation, of which 5,548,084
(MAF>5%) were retained, after QC, for association analysis (Supple-
mentary Figure 2).
Univariate logistic regression analysis of clinical and demographic
variables was undertaken (Table 2). History of hepatic disease, history
of renal disease, history of neurological disease, history of gastro-
intestinal disease, history of duodenal disease, gender, age, antiplate-
let agents, smoking status, H. pylori status and steroids all remained
in the final stepwise model. These 11 variables were used as covari-
ates in the logistic regression between genetic variants and the out-
come.
Table 1
Summary of the discovery and replication cohorts included in the final genetic
analysis.
Discovery Cohort (n) Replication Cohort (n)
PUD § NSAID








Not specified 10 11
Total Cases 235 198







Not Specified 12 10
No PUD §/- NSAID (Control B) 217 78
Aspirin Only 98 1
Non-Aspirin 0 8
Both 11 1
No NSAID 108 68
Total Controls 441 162
* 1 PUD case classified as duodenal and pyloric ulcer
4 S. Bourgeois et al. / EBioMedicine 74 (2021) 103728The results of the logistic regression are presented in Figure 1a
and table 3. Quantiles were plotted (Figure 1b), and the inflation fac-
tor lambda was calculated at 1¢0358, confirming there was no signifi-
cant inflation of p-values due to population structure. After
inspection of regional association plots, two loci in which the leadTable 2
Univariate logistic regression analysis of clinical and demographic covar
Variable Controls (n=441) Missin
*Age (years) (Mean (SD)) 61¢5 (14¢74) 1









AUDIT (Mean (SD)) 4¢3 (5¢9) 1
*H¢pylori positive 167 (41¢4%) 38
Concomitant medications
*Antiplatelet agents 14 (3¢2%) 0
Antisecretory drugs 12 (2¢7%) 0
Anticoagulants 24 (5¢4%) 0
Calcium 47 (10¢7) 0
Proton Pump Inhibitors 188 (42¢6%) 0
Selective Serotonin reuptake inhibitors 37 (8¢4%) 0
*Steroids 17 (3¢9%) 0
Previous History
Cardiovascular Disease 221 (50¢2%) 1
Diabetes Mellitus 45 (10¢4%) 7
*Gastrointestinal Disease 322 (73¢2%) 1
Gastric Disease 18 (4¢1%) 1
*Duodenal Disease 62 (14¢1%) 1
*Hepatic Disease 33 (7¢6%) 8
H¢ pylori infection 80 (18¢2%) 1
Musculoskeletal Problems 183 (42¢1%) 6
*Neurological Disease 36 (8¢2%) 3
*Renal Disease 32 (7¢0%) 3
Respiratory Disease 105 (23¢9%) 1
P-values in bold indicate independent statistically significant associatio
logistic regression model for GWAS analysis.variant was associated at p<105 with a strong delineated signal
were selected for replication. The lead variant on chromosome 8,
rs12678747 (genotyped) (p =1¢65£107 [Logistic Regression (LR)],
OR=2¢05, 95% CI 1¢60-2¢62), did not associate with NSAID use
amongst controls (p=0¢703 [LR]). The signal is clearly delimited and
located in an intron of the gene eyes absent 1 (EYA1) (Figure 1c). The
signal on chromosome 7, rs112772601 (p =2¢96£106 [LR], OR=0¢54,
0¢39-0¢75 CI), is an intronic single nucleotide deletion in the NPSR1
gene locus, (Figure 1d). This variant did not associate with NSAID use
amongst controls (p =0¢054 [LR]). To test rs112772601 for replication
we used a proxy (variant rs9655357, R2=0¢96) which was compatible
with the genotyping assay (TaqMan) used.
Replication was performed in another sample of 515 patients
(replication cohort; Table 1). After accounting for missing clinical and
demographic covariate data in the replication cohort, a total of 198
cases and 162 controls were included in the logistic regression analy-
sis. Both SNPs typed in the replication cohort, rs12678747 and
rs9655357, had call-rates >99¢5% and conformed to Hardy-Weinberg
equilibrium (p >0¢01 [exact test]).
In our replication cohort, the EYA1 SNP (rs12678747) showed
a significant association (p=0¢002 [LR], OR=1¢97; 95% CI 1¢34-2¢92)
when aspirin-associated cases only (n=84) were analysed in keep-
ing with the discovery GWAS, even after Bonferroni correction.
However, limiting the analysis to non-aspirin NSAIDs (n=114) or
by combining all NSAIDs (n=199) did not yield a statistically sig-
nificant association. Meta-analysing the discovery and replication
cohort data, focusing on aspirin intake only, yielded a genome-
wide significant association for rs12678747 (p=3¢12£1011 [LR];
OR=2¢03; 95% CI 1¢65-2¢50).
The proxy for rs112772601, rs9655357, reached nominal sig-
nificance (p=0¢03 [LR]), but combined analysis with the discovery
samples did not reach genome-wide significance (p=1¢64£104
[LR]).iates
g data (n) Cases (n=235) Missing data (n) p-value
70¢2 (10¢4) 2 2¢16£1013





3¢8 (4¢9) 4 0¢289
134 (57¢3%) 1 1¢24£1004
22(9¢4%) 0 1¢12£1003
9 (3¢8%) 0 0¢431
28 (7¢7%) 0 0¢258
33 (14¢0) 0 0¢196
86 (36¢6%) 0 0¢128
15 (6¢4%) 0 0¢352
6 (2¢6%) 0 0¢377
197 (83¢8%) 0 6¢16£1016
74 (31¢5%) 0 6¢21£1011
112 (47¢7%) 0 8¢84£1011
7 (3¢0%) 3 0¢486
45 (19¢3%) 2 0¢079
18 (7¢7%) 0 0¢986
36 (15¢3%) 2 0¢146
114 (48¢5%) 0 0¢110
42 (17¢9%) 0 2¢65£1004
36 (15¢3%) 0 1¢28£1003
57 (24¢3%) 0 0¢910
ns (p<0¢05). *indicates variables included in the optimal stepwise
Figure 1. a. Manhattan plot of the genome wide association analysis of (aspirin)-induced peptic ulcer disease. Y-axis represents log10 p-value for logistic regression analysis and
X-axis indicates the chromosomal position of each SNP. A dotted red line marks the p=1£1006 threshold, and all variants below this threshold are represented by a green dot
instead of a grey/black one. b. Quantile-Quantile plot of the genome wide association analysis of (aspirin)-induced peptic ulcer disease. Y-axis represents log10 p-value for logistic
regression analysis and X-axis indicates log10 of the expected p-values given the number of markers. The 95% confidence interval around expectation is represented in grey. The
lambda inflation factor (1¢0358) is displayed. Regional plots of rs12678747 (c) and rs112772601 (d) showing -log10(p-value) on the left Y-axis, recombination rate on the right Y-
axis, and genomic location (in base pairs) on the X-axis. Pairwise linkage disequilibrium, r square, between the investigated variant (shown as a purple lozenge) and the surrounding
variants is expressed using five colour coding, detailed in the top right-hand corner of each plot. Known genes are presented below the plot as arrows, indicating the location and
size, as well as the direction of transcription, of each gene.
S. Bourgeois et al. / EBioMedicine 74 (2021) 103728 53.1. Expression of EYA1 in gastric biopsy samples
EYAI expression was determined by RNA sequencing in matched
ulcer edge and antrum tissue samples from the 10 biopsies of NSAID-
PUD patients as well as 10 healthy control antrum biopsies. Overall,
expression at the ulcer edge was significantly lower than in the
antrum (p=0¢0015) [Student t-test] (Figure 2), but there was no sig-
nificant difference between ulcer edge and control antrum (p>0¢5).
4. Discussion
Evaluation of deeply-phenotyped patients with endoscopically-
proven PUD and verified history of aspirin intake using a genome-
wide approach has identified, for the first time, an associationbetween common genetic variation in the EYA transcriptional co-
activator and phosphatase 1 (EYA1) locus on chromosome 8 and aspi-
rin-induced PUD. Although the total number of patients analysed in
the discovery GWAS was modest, we were able to replicate the signal
in another set of patients with aspirin-induced PUD (n=84). Our find-
ings are consistent with the finding that pharmacogenomic predis-
posing loci have larger effect sizes than loci identified for complex
diseases [35] which require much larger sample sizes, and rarely
exceed odds ratio >2.
We did not find an association between the EYA1 variant and non-
aspirin NSAID-induced PUD, but the total number of cases was low
and consisted of multiple different NSAIDs. Further work will thus be
needed to determine whether the same EYA1 variant(s) also predis-






















































































































































































































































































































































































Figure 2. EYA1 transcript expression, determined from RNA sequencing, in antrum
and ulcer biopsy tissue from aspirin-induced PUD patients (n=10). EYA counts/million
mapped reads with expression data from all 10 individuals. Grey data points represent
individuals who were positive for H. pylori. Statistically significant difference is
denoted by **p<0¢01 as determined by the Mann-Whitney U test
6 S. Bourgeois et al. / EBioMedicine 74 (2021) 103728NSAIDs and as a therapeutic class). To our knowledge, this is the first
GWAS focusing on aspirin-induced PUD; a previous GWAS in Japa-
nese patients with duodenal ulceration, which did not stratify by
aetiology, identified predisposing loci in the PSCA and ABO blood
group genes [36], but not in EYA1. EYA1 and PSCA are both on chro-
mosome 8 but are 70Mb apart, and the underlying variants are not in
linkage disequilibrium. Furthermore, no significant association with
aspirin PUD was observed in our discovery cohort for either of the
previously reported PSCA or ABO variants (p=0¢14, and p=0¢67,
respectively).
EYA1 gene mutations cause 3 genetic syndromes: branchio-oto-
renal syndrome 1 (MIM 113650), branchio-otic syndrome 1 (MIM
602588) and oto-facio-cervical syndrome 1 (MIM 166780) [37], man-
ifested by a combination of hearing loss, auricular malformations,
branchial arch remnants, and renal anomalies [38]. The phenotypes
of these 3 genetic syndromes are not characterised by spontaneously
occurring peptic ulceration. EYA1 has a number of functions: it acts
as a transcriptional activator for SIX1 [39], it is involved in organ
development [40,41], DNA damage repair and cell survival [42], and
angiogenesis [43]. Importantly, it also acts as a tyrosine phosphatase
[39] that helps to control the apoptotic response by executing a dam-
age-signal-dependent dephosphorylation of an H2AX carboxy-termi-
nal tyrosine phosphate [42]. This modification determines the
relative recruitment of DNA repair or pro-apoptotic factors to the tail
of serine phosphorylated histone deacetylase, which in turn acts as a
“decision maker” as to whether a cell undergoes cell death or repair/
survival as a result of a stress signal [42]. Whether this is important
in the genetic association we have identified will require further
mechanistic evaluation.
Our most significant signal in EYA1 (rs12678747, directly geno-
typed) is an intronic variant. Analysis using the GTex database found
no significant eQTLs in stomach tissue, while initial analysis of the
ENCODE database did not identify any transcription factor binding
sites which are altered by rs12678747 though this does not preclude
the possibility that a SNP in LD may do so. Preliminary PheWAS anal-
ysis of the EYA1 gene locus using the GeneATLAS UK Biobank data-
base showed that there were no statistically significant associations
between EYA1 and any relevant phenotypes. Further fine mapping
and functional studies will thus be required to identify the causal var-
iant.
A recent study utilising the UK Biobank identified loci at or near
the MUC1, MUC6, FUT2, PSCA, ABO, CDX2, GAST and CCKBR genes that
were associated with generalised PUD [44]. However, it is important
S. Bourgeois et al. / EBioMedicine 74 (2021) 103728 7to note that there was no stratification of patients according to aetiol-
ogy (and in particular whether the PUD was due to aspirin and/or
other NSAIDs). Limitations of the UKBB in relation to this phenotype
are that it does not accurately record (a) the use of over-the-counter
medications such as aspirin, (b) the temporal relationship between
when the ulcer was diagnosed and when the patient was actually
exposed to the NSAID may not be clear in all cases, and (c) the diag-
nosis of an ulcer varies, often self-reported, and rarely with evidence
of endoscopic confirmation.
In terms of translation, we calculate that 24 individuals would
need to be tested to prevent one case of aspirin-induced PUD,
although this would need to be confirmed in further studies. Mecha-
nistic knowledge of the role of EYA1 in aspirin-induced peptic ulcera-
tion may also allow the development of new agents for preventing
PUD.
4.1. Caveats and limitations
Our study has limitations. Our overall sample size is smaller than
that seen in complex disease studies as mentioned before [35], but it
is compensated for by the larger effect size, careful phenotyping, and
replication, though we couldn’t ascertain the contribution of rarer
alleles. The total number of patients for the transcriptomic analysis
was low (n=10); it is however extremely difficult to recruit this
patient group who are acutely ill when they attend, and in need of
emergency resuscitation and endoscopy to stop bleeding. Because of
the small number, we limited our analysis to ulcer and control sites
only. As our study relies on a genotyping array and imputation, it is
possible we haven’t captured the causal allele which would require a
deep sequencing-based approach.
In conclusion, we have identified that common genetic variants in
the EYA1 gene predispose to aspirin-induced peptic ulceration. Our
findings do not diminish the importance of the prostanoid hypothesis
in the pathogenesis of NSAID-induced peptic ulceration, but are con-
sistent with our increasing knowledge that multiple steps are
involved in the mechanism by which NSAIDs (including aspirin)
induce peptic ulceration [17]. Further work is required to fully under-
stand the mechanisms of our findings, and potential consequences
for translation.
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